wealthyvc

[wealthyvc]

Sober Up, Buttercup: Why Quantum BioPharma’s Alcohol Detox Drink unbuzzd™ is a Game-Changer

Unlike traditional hangover remedies, unbuzzd is a proactive solution designed to optimize alcohol metabolism and alleviate common symptoms such as dehydration, brain fog, and sluggishness. The formula boasts a blend of natural ingredients which work synergistically to hydrate, detoxify, and boost cognitive function within 30 minutes of consumption.

On February 4th, Quantum reported the completion of the unbuzzd clinical trial, and the results sent the stock skyrocketing from $3.18 to a high of $18 in under a week—a gain of 466%.

The purpose of the clinical trial was to investigate the effects of unbuzzd on alcohol metabolism and intoxication.

Compared to the placebo group, the study’s results were statistically significant and clearly showed that unbuzzd accelerated the reduction of blood alcohol concentration in the study subjects while simultaneously alleviating the symptoms of intoxication and hangover.

Key Findings From the unbuzzd Clinical Trial:

- Accelerated alcohol metabolism.

- Rapid improvements in alertness.

- Rapid improvements in physiologic changes due to intoxication. - Reduced perceived impairment and mental fatigue. - Hangover relief. - No side effects.

Backed by a team of heavy hitters, including former Celsius Holdings CEO Gerry David, ex-Coca-Cola VP John Duffy, and original Shark Tank investor Kevin Harrington, unbuzzd is poised to shake up the multibillion-dollar functional beverage market.

The team behind unbuzzd includes industry veterans who have previously transformed the functional beverage market. Gerry David’s leadership at Celsius turned the company into a global powerhouse, delivering a 35X increase in market cap.

Over the past 10 years, Celsius has been one of the top-performing stocks in the entire market. From a low of $0.10 in 2014 to its recent 52-week high of $99.62, Celsius generated a 10-year return of 99,520%.

The playbook that propelled Celsius to its massive success is now being applied to unbuzzd.

For those interested in trying out the product, unbuzzd is available for purchase on Amazon and unbuzzd.com.

Disclaimer: https://wealthyvc.com/disclaimer/

[wealthyvc]

Shuttle Pharmaceuticals (NASDAQ: SHPH) Might Be the Most Undervalued Biotech Stock on the Market Today, Here's Why

Significant valuation discrepancies currently exist within the biotech sector, creating an environment ripe with hidden gems.

Shuttle Pharma's tiny valuation of only $4 million stands in stark contrast to several of its peers in Phase 2 clinical trials, which boast market caps 12,000% higher at more than $500 million.

Biotech valuations often evolve significantly as companies progress through clinical trials. For Phase 1 assets, the average valuation tends to hover between $100 – $250 million, while Phase 2 assets range from $250 – $750 million. Valued at just $4 million, Shuttle Pharma is an outlier, suggesting it should be 25x higher based on similar Phase 2 comparables.

This mismatch reflects a significant opportunity for investors, as Shuttle is already enrolling patients in its Phase 2 trial for Ropidoxuridine. If Ropidoxuridine demonstrates efficacy, the company could see valuations 100x higher, reflecting the immense upside potential.

Radiation therapy is a cornerstone of cancer treatment, with approximately 50% of cancer patients undergoing it during their illness.

Ropidoxuridine is Shuttle Pharma's flagship radiation sensitizer in Phase 2 trials for glioblastoma. As a sensitizer, it enhances the vulnerability of cancer cells to radiation while sparing healthy tissues, leading to improved therapeutic outcomes.

This approach revolutionizes therapy by increasing tumor control and minimizing harmful side effects, particularly for aggressive cancers like glioblastoma. Shuttle Pharma’s Ropidoxuridine is at the forefront of this innovation.

Ropidoxuridine has received an Orphan Drug Designation from the FDA, ensuring market exclusivity upon approval. Early data supports its safety and oral bioavailability, with promising mechanisms to sensitize cancer cells without harming normal tissues.

Founded by Georgetown University faculty, Shuttle Pharmaceuticals is led by experienced scientists and executives with decades of oncology expertise. The management team includes individuals responsible for bringing successful cancer therapies to market, further bolstering its credibility.

Click here for full details: https://wealthyvc.com/featured/heres-why-shuttle-pharma-is-the-most-undervalued-biotech-stock-in-our-coverage-universe/

Disclaimer: https://wealthyvc.com/disclaimer/